EAMS don't underestimate it's potential! Ok her
Post# of 155256
(Total Views: 501)
Posted On: 09/17/2020 11:49:49 AM
Re: nicehedges #56576
EAMS don't underestimate it's potential!
Ok here are all of Kush's comments regarding EAMS. His warm and loveable voice is always a plus ( I believe he may be the human reincarnation of the Pillsbury doughboy ), but I think each word he uttered is important here.
Kush was on the call and heard first hand what MHRA is asking for.. it is MHRA's idea to approve us for EAMS and CYDY is already providing what they are asking for per the second half of Kush's quote. It also sounds like a follow up meeting is in the works. That would have been a good point to raise during Q+A.
Consider how impactful the news would be if MHRA grants EAMS access. This would be the instant validation of Leronlimab we are in desperate need of to allow so many other things to fall in place.. share price appreciation about $4 --->Nasdaq --->BP interest --->....
“MHRA has recommended that Leronlimab might be a good candidate for Early access to Medicines Scheme or called EAMS. Under this EAMS approval patients in the UK will be allowed to have access to Leronlimab prior to it’s full marketing authorization. As Dr. Pourhassen mentioned, MHRA has recommended us to submit the data from our 60+ patients from the emergency IND’s and in combination with the data from other ongoing studies, so that submission process is already initiated our team has started working on it and compiling all the data to share with the MHRA with the followup on that meeting. ”
Ok here are all of Kush's comments regarding EAMS. His warm and loveable voice is always a plus ( I believe he may be the human reincarnation of the Pillsbury doughboy ), but I think each word he uttered is important here.
Kush was on the call and heard first hand what MHRA is asking for.. it is MHRA's idea to approve us for EAMS and CYDY is already providing what they are asking for per the second half of Kush's quote. It also sounds like a follow up meeting is in the works. That would have been a good point to raise during Q+A.
Consider how impactful the news would be if MHRA grants EAMS access. This would be the instant validation of Leronlimab we are in desperate need of to allow so many other things to fall in place.. share price appreciation about $4 --->Nasdaq --->BP interest --->....
“MHRA has recommended that Leronlimab might be a good candidate for Early access to Medicines Scheme or called EAMS. Under this EAMS approval patients in the UK will be allowed to have access to Leronlimab prior to it’s full marketing authorization. As Dr. Pourhassen mentioned, MHRA has recommended us to submit the data from our 60+ patients from the emergency IND’s and in combination with the data from other ongoing studies, so that submission process is already initiated our team has started working on it and compiling all the data to share with the MHRA with the followup on that meeting. ”
(2)
(0)